| Literature DB >> 27113334 |
L L Jasper1, C A Jones2, J Mollins3, S L Pohar4, L A Beaupre1.
Abstract
BACKGROUND: In spite of the increasing incidence of total knee arthroplasties (TKA), evidence is limited regarding risk factors for revision. The objective of this scoping review was to identify and assess demographic, surgical and health services factors that may increase the risk for revision surgery following TKA.Entities:
Keywords: Failure; Revision; Risk factor; Scoping review; Total knee arthroplasty
Mesh:
Year: 2016 PMID: 27113334 PMCID: PMC4845333 DOI: 10.1186/s12891-016-1025-8
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Fig. 1PRISMA flow diagram
Survival rates at 10 and 20 Yearsa
| Author(s), year | Duration of follow-up (yrs) | Index procedure (n) | Revision (n) | Survival rate (%, CI) |
|---|---|---|---|---|
| Badawy M. et al., 2013 [ | 10 | 26,698 | 1169 | Low hospital volumeb: 92.5 %, 95 % CI 91.5 to 93.4 |
| Gothesen, Ø. et al., 2013 [ | 10 | 17,782 | NR | 89.5 to 95.3 %, CI- NR |
| Himanen, A. et al., 2007 [ | 10 | 751 | 37 | Prosthetic moulded component: 94.4 %, 95 % CI 90.4 to 96.7 |
| Jämsen, E. et al., 2013 [ | 10 | 53,007 | 1919 | 94.5 %, 95 % CI 94.1 to 94.8 |
| Rand, J. et al., 2003 [ | 10 | 11,606 | NR | 91 %, 95 % CI 90 to 91 % |
| Vessely, M. et al., 2006 [ | 10 | 1000 | 45 | 98.6 %, 95 % CI 97.8 to 99.4 |
| Fang, D. et al., 2009 [ | 20 | 6070 | 51 | 99 %, CI - NR |
| Rand, J. et al., 2003 [ | 20 | 11,606 | NR | 78 %, 95 % CI 74 to 81 % |
aSee Additional file 2 for further detail. Not reported in publication, NR
bLow hospital volume is 1–24 TKA performed per year; High hospital volume is ≥150 TKA performed per year
Sex and adjusted risk of revisiona
| Author(s)/year | Control | Hazard ratio (CI) |
|---|---|---|
| Blum, M. et al., 2013 [ | Female | 0.81, 95 % CI 0.71 - 0.92, |
| Fehring, T. et al., 2004 [ | Male | 2.771, 99 % CI 1.662 - 4.620, |
| Harrysson, O. et al., 2004 [ | Male | 1.64, 95 % CI 1.23 - 2.18, |
| Rand, J. et al., 2003 [ | Male | 1.6, 95 % CI 1.4 - 2.0, |
| Schrama, J. et al., 2010 [ | Female | 0.67, 95 % C I 0.47 - 0.88 |
| Stiehl, J. et al., 2006 [ | Female | 1.513, 95 % CI 1.116 - 2.051 |
aSee Additional file 2 for further detail
Age and adjusted risk of revisiona
| Author(s)/Year | Age | Hazard ratio (95 % CI) |
|---|---|---|
| Bini, S. et al., 2013 [ | >55 years | 0.43, 95 % CI 0.27 to 0.67, |
| Blum, M. et al., 2013 [ | 18–64 years vs. 65+ yrs | 2.30, 95 % CI 1.96 to 2.69, |
| Bordini, B. et al., 2009 [ | Age at surgery (per year) | 1.05, 95 % CI 1.03 to 1.06, |
| Fehring, T. et al., 2004 [ | Age at surgery (per year) | 0.953, 99 % CI 0.932 to 0.975, |
| Gioe, T. et al., 2004 [ | Age <70 year | 0.46, 95 % CI.0.33 to 0.64, |
| Harrysson, O. et al., 2004 [ | Older patients (≥60 year) | 0.49, 95 % CI 0.38 to 0.62, |
| Julin, J. et al., 2010 [ | Age ≤ 55 years: | 2.9, 95 % CI 2.3 to 3.6 |
| Age 56–65 years: | 1.7 95 % CI 1.4 to 2.0 | |
| Kreder, H. et al., 2003 [ | Younger age per 10 year: | OR 0.77, 95 % CI 0.67 to 0.89 |
| Lygre, S. et al., 2011 [ | Age >70 year vs. <60 year | 0.4, 95 % CI 0.3–0.4, 0 < 0.001 |
| Namba, R. et al., 2013 [ | Age (increasing 10 year increments) | 0.62, 95 % CI 0.57 to 0.67, |
| Namba, R. et al., 2012 [ | Age (increasing 10 year increments) | 0.64, 95 % CI 0.58 to 0.70, |
| Rand, J. et al., 2003 [ | Age 56–70 year vs. ≤55 years | 0.7, 95 % CI 0.5 to 0.9, |
| Stiehl, J. et al., 2006 [ | Younger patients (for every yr increase) | 0.979, 95 % CI 0.968 to 0.989 |
aSee Additional file 2 for further detail
Implant type/technique and adjusted risk of revisiona
| Author(s)/year | Implant type/technique | Reference | Hazard ratio (95 % CI) unless otherwise stated |
|---|---|---|---|
| Abdel, M. et al., 2011 [ | Cruciate Status: | ||
| Posterior cruciate-retaining | Posterior cruciate-stabilizing | 0.5, 95 % CI 0.4 - 0.6, | |
| Rand, J. et al., 2003 [ | Cruciate Status: | ||
| Posterior Stabilized | Posterior cruciate-retaining | 2.6, 95 % CI 2.1 - 3.5, | |
| Constrained condylar | Posterior cruciate-retaining | 2.1, 95 % CI 0.9 - 4.9, | |
| Stiehl J. et al., 2006 [ | Cruciate Status | ||
| PCRs | Rotating platform | 1.552, 95 % CI 1.157 - 2.081 | |
| BCRs | 2.188, 95 % CI 1.454 - 3.294 | ||
| Gøthesen, O. et al., 2013 [ | Implant Type: | ||
| Duracon | Profix | 2.6, 95 % CI 1.9 - 3.4, | |
| LCS Classic HR | 1.3, 95 % CI 1.0 - 1.6, | ||
| LCS Complete | 1.5, 95 % CI 1.1 - 1.9, | ||
| AGC Universal | 1.6, 95 % CI 1.3 - 2.0, | ||
| Lygre, S. et al., 2010 [ | Implant Type: | Relative Risk = | |
| NR Tricon | NR AGC Universal | 1.67, 95 % CI 1.24–2.24, | |
| NR Genesis 1 | 1.43, 95 % CI 1.14–1.79, | ||
| NR Duracon | 1.45, 95 % CI 1.05–1.99, | ||
| NR Profix | 0.66, 95 % CI 0.52–0.82, | ||
| NR e.motion | 0.09, 95 % CI 0.02–0.37, | ||
| NR AGC anatomic | 0.66, 95 % CI 0.45–0.99, | ||
| PR AGC universal | 0.48, 95 % CI 0.27–0.83, | ||
| PR NexGen | 0.40, 95 % CI 0.22–0.74, | ||
| Namba R. et al., 2013 [ | Implant Type: | ||
| Rotate LCS | Fixed PS | 2.07, 95 % CI 1.53 - 2.80, | |
| High flexion | Yes versus No | 1.76, 95 % CI 1.29 - 2.41, | |
| Namba R. et al., 2012 [ | Implant Type: | ||
| LCS | Fixed | 2.01, 95 % CI 1.41 - 2.86, | |
| Inacio M. et al., 2013 [ | Bearing or inserts: | ||
| CoCr-HXLPE | CoCr-CPE | NS 1.2, 95 % CI 0.9 - 1.5, | |
| OZ-CPE | C0Cr-CPE | NS 1.4, 95 % CI 0.3 - 5.9, |
Abbreviations: RR relative risk, NS not significant, BCR bicruciate preservation, PCR posterior cruciate retention, (PR) patella resurfaced, (NR) patella non resurfaced, LCS low contact stress, OZ oxidized zirconium, CoCR cobalt chromium, CPE conventional polyethylene, HXLPE highly crosslinked polyethylene;
aSee Additional file 2 for further detail